Monte Rosa Therapeutics will present interim clinical results for MRT-2359 in a conference call on December 16, 2025.
Quiver AI Summary
Monte Rosa Therapeutics, Inc. announced a live conference call and webcast scheduled for December 16, 2025, at 8:00 a.m. ET, to present interim clinical results from its ongoing Phase 1/2 trial of the GSPT1-directed molecular glue degrader MRT-2359, aimed at treating heavily pretreated patients with metastatic castration-resistant prostate cancer. The webcast can be accessed through Monte Rosa’s website, with an archived version available for 30 days after the event. Monte Rosa specializes in developing selective molecular glue degrader medicines for serious diseases, using its QuEEN discovery engine to design highly effective treatments. The company boasts a strong pipeline of innovative therapies across various fields, including oncology and autoimmune diseases, and is engaged in collaborations with major pharmaceutical partners.
Potential Positives
- Monte Rosa Therapeutics is showcasing interim clinical results for its MRT-2359, which may indicate promising developments in the treatment of metastatic castration-resistant prostate cancer, a challenging condition.
- The company highlights its unique QuEEN™ discovery engine that enhances its ability to develop highly selective molecular glue degraders, setting it apart in the biotechnology field.
- Monte Rosa has established itself with an industry-leading pipeline of first-in-class and only-in-class MGDs, demonstrating its innovative capabilities and potential for market leadership.
- The live webcast offers an opportunity for investors and the public to engage with the company's latest developments, potentially enhancing transparency and stakeholder confidence.
Potential Negatives
- The press release does not provide any concrete data or outcomes from the interim clinical results, leaving investors and stakeholders without valuable insights into the effectiveness of the MGD MRT-2359 treatment.
- There is no mention of any positive results or advancements from the ongoing clinical trials, which may raise concerns about the progress of the company's pipeline.
- The focus on heavily pretreated, metastatic castration-resistant prostate cancer patients could imply limited effectiveness or challenges in treating this patient population, raising questions about the viability of MRT-2359 as a competitive treatment option.
FAQ
What is the purpose of the Monte Rosa Therapeutics conference call?
The conference call will present interim clinical results from the Phase 1/2 study of MRT-2359 in prostate cancer patients.
When is the Monte Rosa Therapeutics conference call scheduled?
The conference call is scheduled for Tuesday, December 16, 2025, at 8:00 a.m. ET.
How can I access the Monte Rosa Therapeutics webcast?
The webcast can be accessed via the “Events & Presentations” section on Monte Rosa’s website at ir.monterosatx.com.
How long will the archived version of the webcast be available?
The archived version of the webcast will be available for 30 days following the presentation.
What does Monte Rosa Therapeutics specialize in?
Monte Rosa specializes in developing molecular glue degrader medicines for serious diseases using advanced technologies like AI and structural biology.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GLUE Hedge Fund Activity
We have seen 61 institutional investors add shares of $GLUE stock to their portfolio, and 70 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AVORO CAPITAL ADVISORS LLC removed 3,725,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $27,602,250
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,688,598 shares (-26.7%) from their portfolio in Q3 2025, for an estimated $12,512,511
- VESTAL POINT CAPITAL, LP added 800,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $5,928,000
- SILVERARC CAPITAL MANAGEMENT, LLC added 694,942 shares (+inf%) to their portfolio in Q3 2025, for an estimated $5,149,520
- AQR CAPITAL MANAGEMENT LLC removed 566,680 shares (-44.1%) from their portfolio in Q3 2025, for an estimated $4,199,098
- FMR LLC added 524,217 shares (+22.9%) to their portfolio in Q3 2025, for an estimated $3,884,447
- MARSHALL WACE, LLP added 456,754 shares (+102.4%) to their portfolio in Q3 2025, for an estimated $3,384,547
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Tuesday, December 16, 2025, at 8:00 a.m. ET. The webcast presentation will highlight interim clinical results from the ongoing Phase 1/2 study of the GSPT1-directed MGD MRT-2359 in heavily pretreated, metastatic castration-resistant prostate cancer (mCRPC) patients.
A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com . Registration for the conference call is available at the following link . An archived version of the webcast will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology and neurology. For more information, visit
www.monterosatx.com
.
Investors
Andrew Funderburk
[email protected]
Media
Cory Tromblee, Scient PR
[email protected]
